Transfer of emicizumab into breast milk in postpartum acquired hemophilia A.
Simon Alexander Krooss, Tim Halling, Dirk Varnholt et al.
✦ AI-curated · Sources linked
Case in brief
A woman developed acquired hemophilia A (AHA) four months postpartum and was treated with emicizumab while breastfeeding. Analysis of her plasma and breast milk revealed that emicizumab was detectable in breast milk at concentrations up to 20 μg/mL, while anti-FVIII antibodies were present in plasma but absent in breast milk. This case highlights the transfer of emicizumab into breast milk.
Diagnostic / clinical pearl
Emicizumab can be detected in breast milk, which is important for counseling breastfeeding women with postpartum acquired hemophilia A.
Why it matters
Understanding the transfer of emicizumab into breast milk is crucial for informed decision-making regarding breastfeeding in women undergoing treatment for AHA.